Navigation Links
VetNostic Laboratories® Announces New Testing for Dog Breeds
Date:10/27/2011

HAMILTON, N.J., Oct. 27, 2011 /PRNewswire/ -- VetNostic Laboratories® offers state-of-the-art genetic testing services for dog breeders and owners. Using DNA analysis, they are able to accurately and specifically determine whether or not a dog carries disease-causing genes. Providing reliable identification of these "carriers" ensures healthy litters and a successful breeding program. At this time, VetNostic Laboratories® is pleased to introduce two new tests to its growing diagnostic menu, Primary Lens Luxation and Greyhound Polyneuropathy.

Primary Lens Luxation (PLL) is a potentially blinding inherited disease in many Terrier breeds. It occurs when the ligaments holding the lens of the eye break down, causing it to dislocate. This can result in painful, teary, red eyes that may look hazy or cloudy. If not diagnosed and properly treated, PLL may lead to Uveitis and/or Glaucoma. This test is relevant to the following breeds: American Eskimo Dog, American Hairless (Rat) Terrier, Australian Cattle Dog, Chinese Crested, Chinese Foo Dog, Jack Russell Terrier, Jagd Terrier, Lakeland Terrier, Lancashire Heeler, Miniature Bull Terrier, Parson Russell Terrier, Rat Terrier, Russell Terrier, Sealyham Terrier, Teddy Roosevelt Terrier, Tenterfield Terrier, Tibetan Terrier, Toy Fox Terrier, Volpino Italiano, and Welsh Terrier.

Greyhound Polyneuropathy is a fatal neurological disease specific to the Greyhound show dog population. Symptoms include decreased or absent reflexes, muscle weakness, muscle pain and cramps, and a bunny-hopping gait. It usually appears within the first 9 months of age and then progresses so quickly that most affected dogs must be euthanized within their first year of life. Currently, there is no effective treatment for Greyhound Polyneuropathy.

VetNostic Laboratories® genetic tests for PLL and Greyhound Polyneuropathy can reliably identify dogs that are either clear, or possess one or two copies of the disease-causing genes which they may pass to their offspring. This clear, carrier, or affected result can help breeders determine which animals to include in their breeding programs.

Dr. Martin E. Adelson, Vice President of the Genesis Biotechology Group, stated, "We are pleased to continually add to the diversity of testing services offered by VetNostic Laboratories®. These most recent tests will help breeders to eliminate diseases such as PLL and Greyhound Polyneuropathy from future generations. This testing also provides true value to breeders as they can authenticate that their puppies are clear of common disorders caused by genetic mutations. It's an exciting time in the field of canine molecular diagnostics."

VetNostic Laboratories®, a division of Medical Diagnostic Laboratories, L.L.C., is a company within the Genesis Biotechnology Group. They are located in "Einstein's Alley," the research and technology corridor in Hamilton, New Jersey. Their facility is easily accessible in the New York, New Jersey, and Pennsylvania area.

VetNostic Laboratories® offers a web-based shopping cart to make molecular diagnostic testing readily available to the dog breeder and owner communities. Through this online ordering system, they are able to view test descriptions and order specimen collections kits. Specimen collection instructions and a "How-To" video facilitate step-by-step collection of cheek swabs from dogs.

To find out more, please visit http://www.vetnostic.com

Contact:

Rob Mason
Research Scientist
rmason@vetnostic.com
877.255.9208
http://www.vetnostic.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE VetNostic Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Disappearing forests ... the lives of over 5.5 million people each year. Especially those living in larger ... startup Treepex - based in one of the most pollution-affected countries globally - decided ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:8/15/2017)... ivWatch LLC , a medical device company focused on improving the ... its ISO 13485 Certification, the global standard for medical device quality ... ... device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it validates ...
(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
Breaking Biology News(10 mins):